Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study

Authors :: Elisabetta Cretella
Marina Elena Cazzaniga
Michela Roberto
Laura Iezzi
Giuseppina Sarobba
A. Turletti
Luca Clivio
Stefania Pedroli
Cristiana Taverniti
Giovanni Scognamiglio
A. Gambaro
Anna Maria Vandone
Daniele Generali
A. Ferzi
Emilia Montagna
Mariangela Ciccarese
Valter Torri
Pietro Spadaro
Carmela Mocerino
Paolo Tralongo
Source :: Journal of Clinical Oncology. 36:e13076-e13076
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e13076Background: mCHT is the minimum biologically effective dose of a CHT agent, given at regular dosing regimen with no prolonged drug free interval. Aim of this observational retrospective study...

Subjects :: Oncology
Drug
Cancer Research
medicine.medical_specialty
business.industry
media_common.quotation_subject
Advanced breast
Dosing regimen
Retrospective cohort study
Effective dose (radiation)
Metronomic Chemotherapy
humanities
Free interval
Internal medicine
Medicine
Observational study
business
media_common

Full Text Access

Tools